Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) | 1 | Y | 1 MK-3475 (pembrolizumab) | 56 | 39 | 12 | 4 | 3 | 0 | 0 | 02/06/2017 | 92 | 40 |
| 39 | 12 | 4 | 3 | 0 | 0 | |||||||||
| S1607-MELAN, Adv, T-VEC, MK-3475 | 1 | Y | 1 T-VEC + MK-3475(pembrolizumab) | 64 | 43 | 23 | 14 | 8 | 1 | 0 | 06/05/2018 | 57 | 23 | |
| 43 | 23 | 14 | 8 | 1 | 0 | |||||||||
| S1616-MELAN, Adv, Ipilimumab ± Nivolumab | 1 | Y | 1 Ipilimumab | 94 | 24 | 12 | 6 | 3 | 1 | 0 | 10/23/2017 | 240 | 100 | |
| 2 Nivolumab + Ipilimumab | 69 | 35 | 17 | 9 | 2 | 0 | ||||||||
| 93 | 47 | 23 | 12 | 3 | 0 | |||||||||
| S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab | 1 | Y | 1 Adjuvant Arm | 556 | 63 | 46 | 22 | 7 | 1 | 0 | 02/15/2019 | 309 | 130 | |
| 2 Neoadjuvant Pembrolizumab | 64 | 48 | 23 | 8 | 4 | 0 | ||||||||
| 127 | 94 | 45 | 15 | 5 | 0 | |||||||||
| 2 | Y | 3 Surgery | 556 | 112 | 95 | 44 | 16 | 2 | 2 | 02/15/2019 | ||||
| 112 | 95 | 44 | 16 | 2 | 2 | |||||||||
| 3 | Y | 4 Post-Surgery Pembro | 556 | 93 | 88 | 45 | 17 | 5 | 0 | 02/15/2019 | ||||
| 93 | 88 | 45 | 17 | 5 | 0 | |||||||||
| Yes | EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T | 1 | E | Total Registrations | 49 | 9 | 4 | 2 | 1 | 1 | 11/03/2015 | 298 | 129 | |
| 49 | 9 | 4 | 2 | 1 | 1 | |||||||||
| 2 | E | Total Registrations | 16 | 2 | 2 | 0 | 0 | 0 | 11/03/2015 | |||||
| 16 | 2 | 2 | 0 | 0 | 0 | |||||||||
| EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim | 1 | E | Total Registrations | 36 | 0 | 0 | 0 | 0 | 0 | 03/25/2016 | 203 | 80 | ||
| 36 | 0 | 0 | 0 | 0 | 0 | |||||||||
| No | EA6174-Merkel, Adjuvant Pembrolizumab vs Observation | 1 | E | Total Registrations | 11 | 10 | 8 | 2 | 0 | 0 | 05/01/2019 | 170 | 93 | |
| 11 | 10 | 8 | 2 | 0 | 0 | |||||||||